-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linperlisib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linperlisib in Follicular Lymphoma Drug Details: Linperlisib (Intarel) is an antineoplastic agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Triple-Negative Breast Cancer (TNBC) Drug Details: Lurbinectedin (Zepzelca)...
-
Sector Analysis
mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape
mRNA Vaccines in Infectious Diseases Market Report Overview The first mRNA vaccines for COVID-19 gained authorization for use in December 2020. These vaccines have been proven highly successful clinically and commercially, dominating the COVID-19 vaccine market. Furthermore, the success of the COVID-19 mRNA vaccines has renewed interest in mRNA vaccines for a variety of other infectious diseases such as influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), Mpox, herpes, Zika virus, and Lyme disease. The report provides an assessment of the...
-
Product Insights
Seasonal Influenza Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Seasonal Influenza Clinical Trial Report Overview A total of 310 seasonal influenza clinical trials were conducted as of February 2024. The Seasonal Influenza clinical trial report provides a comprehensive understanding of the seasonal influenza clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Sector Analysis
Sweden General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
Sweden General Insurance Market Report Overview The gross written premium of the Sweden general insurance market was SEK102.5 billion ($10.1 million) in 2023 and is expected to achieve a CAGR of more than 4% during 2024-2028. The Sweden general insurance market research report provides in-depth market analysis, including insights into the lines of business in the country’s general insurance industry. Furthermore, the report provides a detailed outlook by product category as well as values for key performance indicators, including gross...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EQU-001 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EQU-001 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EQU-001 in Epilepsy Drug Details: EQU-001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sym-024 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sym-024 in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sym-024 in Malignant Pleural Mesothelioma Drug Details: Sym-024 is under...
-
Product Insights
Smallpox – Drugs In Development, 2023
Global Markets Direct’s, ‘Smallpox - Drugs In Development, 2023’, provides an overview of the Smallpox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...